Trial intelligence / Profile preview

IFM/DFCI 2009 trial of RVD versus early autologous stem cell transplant in newly diagnosed multiple myeloma

2009-016871-32Phase 3Completed

Sponsor: Centre hospitalier universitaire de Toulouse
Start: Mar 2010
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
Countries: 1

Overview

Phase 3, randomised, open-label trial of lenalidomide, bortezomib, dexamethasone and melphalan in multiple myeloma (MM) (2 arms), sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Progression-free survival. Started Mar 2010; status: completed.

Drugs

lenalidomidebortezomibdexamethasonemelphalan

Conditions

multiple myeloma (MM)

Beyond the preview

Go deeper on 2009-016871-32.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2009-016871-32.